Viridian Therapeutics/VRDN

$20.94

6.78%
-
1D1W1MYTD1YMAX

About Viridian Therapeutics

Viridian Therapeutics, Inc. is a biotechnology company focused on discovering and developing medicines for serious and rare diseases. The Company is engaged in developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that is developed for intravenous (IV) or subcutaneous administration to treat patients who suffer from thyroid eye disease (TED). Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. It has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED. VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001.

Ticker

VRDN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Stephen Mahoney

Employees

86

Headquarters

Waltham, United States

VRDN Metrics

BasicAdvanced
$979.76M
Market cap
-
P/E ratio
-$5.10
EPS
1.12
Beta
-
Dividend rate

What the Analysts think about VRDN

Analyst Ratings

Majority rating from 15 analysts.
Buy

Price Targets

Average projection from 15 analysts.
87.54% upside
High $50.00
Low $29.00
$20.94
Current price
$39.27
Average price target

VRDN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-47.6M
-13.45%
Profit margin
0%
-

VRDN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.91%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$1.13
-$1.61
-$1.27
-$1.09
-
Expected
-$0.73
-$1.02
-$1.29
-$1.27
-$1.00
Surprise
55.22%
57.91%
-1.89%
-13.91%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Viridian Therapeutics stock

Buy or sell Viridian Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing